InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
60,849.48
(
-0.07%
)
Post# of 252431
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119956
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rfj1862 post# 42338

Wednesday, 02/21/2007 6:08:48 PM

Wednesday, February 21, 2007 6:08:48 PM

Post# of 252431
>While DX-88 in CTS can be a blockbuster just because of sheer patient numbers, DYAX cannot charge an unlimited amount for it as it can for an orphan such as HAE. So, HAE patients will pay through the nose for DX-88 until CTS is approved at which time price will drop.<

DYAX may try to avert this predicament by coming up with non-fungible formulations for the two indications.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up